HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

rozibafusp alfa

Also Known As:

AMG 570; rozibafusp alfa protein, human

Networked: 3 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - Recombinant Fusion Proteins: 333
      - rozibafusp alfa: 3

Experts

1.	Chen, Ching: 1 article (11/2019)
2.	Gaida, Kevin: 1 article (11/2019)
3.	Gunasekaran, Kanna: 1 article (11/2019)
4.	Hsu, Hailing: 1 article (11/2019)
5.	Ishida, Katsu: 1 article (11/2019)
6.	Jacobsen, Frederick: 1 article (11/2019)
7.	Knize, Anna: 1 article (11/2019)
8.	Lee, Francis: 1 article (11/2019)
9.	Miner, Kent: 1 article (11/2019)
10.	Whoriskey, John: 1 article (11/2019)

Related Diseases

1.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/01/2023 - "These results informed the design and dose selection of a phase IIb study assessing the safety and efficacy of rozibafusp alfa in patients with active systemic lupus erythematosus." 11/01/2019 - "Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment."
2.	Rheumatoid Arthritis 11/01/2019 - "By targeting both ICOSL and BAFF, AMG 570 has the potential to achieve superior efficacy in treatment of autoimmune diseases such as SLE and rheumatoid arthritis." 10/01/2022 - "Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study." 10/01/2022 - "To assess the safety and biological activity of rozibafusp alfa, a first-in-class bispecific antibody-peptide conjugate targeting inducible costimulator ligand (ICOSL) and B cell activating factor (BAFF), in patients with rheumatoid arthritis (RA). "
3.	Autoimmune Diseases (Autoimmune Disease) 10/01/2022 - "Findings support further clinical evaluation of rozibafusp alfa in autoimmune disease." 11/01/2019 - "We also generated AMG 570, an ICOSL and BAFF bispecific inhibitory molecule, for potential treatment of autoimmune diseases such as SLE. " 11/01/2019 - "By targeting both ICOSL and BAFF, AMG 570 has the potential to achieve superior efficacy in treatment of autoimmune diseases such as SLE and rheumatoid arthritis."

Related Drugs and Biologics

1.	B-Cell Activating Factor
2.	Ligands
3.	Peptides (Polypeptides)